Responses
Regular and Young Investigator Award Abstracts
Combination Immunotherapies
801 Risk-benefit ratio in immunotherapy (IO) with or without chemotherapy (CT) according to PD-L1 expression: a model-based approach to inform treatment decisions in metastatic non-small cell lung cancer
Compose a Response to This Article
Other responses
No responses have been published for this article.